Lincoln Pharmaceuticals Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
- September 11, 2026
- Posted by: Harsh Piplani
- Category: Results
Lincoln Pharmaceuticals share price Rs 626.05 on 11 September 2026, down 1.02%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 36.00 crore. Q2 FY26 base a profit of Rs 20.00 crore.
Quick Answer
The Lincoln Pharmaceuticals Q2 results date for FY27 is not confirmed, and Lincoln Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 11 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 163.00 crore in revenue and a profit of Rs 20.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.
The Lincoln Pharmaceuticals Q2 results FY27 announcement is the next scheduled earnings event for Lincoln Pharmaceuticals Ltd., an Ahmedabad based maker of finished pharmaceutical formulations in tablet, capsule, injectable and liquid form, selling in India and exporting to markets across Africa, Latin America and Southeast Asia. The stock traded at Rs 626.05 on the NSE on 11 September 2026, down 1.02% from the previous close of Rs 632.50, about 20.8% below its 52-week high of Rs 790.00 and 39.1% above its 52-week low of Rs 450.10.
What makes the Lincoln Pharmaceuticals Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 163.00 crore of revenue and a profit of Rs 20.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 177.00 crore and a profit of Rs 36.00 crore. Everything below is built from those reported figures rather than from any forecast.
Click Here – Get Free Investment Predictions
When Is the Lincoln Pharmaceuticals Q2 Results FY27 Date?
The Lincoln Pharmaceuticals Q2 results date for FY27 is not confirmed. As of 11 September 2026, Lincoln Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.
What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Lincoln Pharmaceuticals Q2 results date becomes public through that filing rather than through any advance announcement.
The Lincoln Pharmaceuticals Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Lincoln Pharmaceuticals.
Lincoln Pharmaceuticals Q2 Results Expectations: What the Market Is Actually Tracking
No verified analyst estimate for the Lincoln Pharmaceuticals Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Lincoln Pharmaceuticals. The Lincoln Pharmaceuticals Q2 results watchlist below is built from what the company has actually reported and disclosed.
The first is revenue, which was Rs 163 crore in September 2025 against Rs 177 crore in Q1 FY27, a rise of about 9%. Sales have grown steadily from Rs 154 crore across the window with no break in the series.
The second is the operating margin, which was 16% in September 2025 and 15% in Q1 FY27. The band is a narrow 13% to 16% throughout, so the operating line has been the stable part of this statement.
The third is the other income line, which is doing most of the work. It swung from negative Rs 4 crore in March 2026 to positive Rs 24 crore in June 2026, a Rs 28 crore move, while operating profit changed only from Rs 25 crore to Rs 27 crore. That swing is what took net profit from Rs 12 crore to Rs 36 crore.
Check Lincoln Pharmaceuticals Ltd. Live Fundamentals on the Univest Screener
Lincoln Pharmaceuticals Q2 Results Preview: The Q1 FY27 Actuals It Builds On
Lincoln Pharmaceuticals Ltd. reported revenue of Rs 177.00 crore in Q1 FY27, up 14.94% from Rs 154.00 crore in Q1 FY26, and a profit of Rs 36.00 crore at the net level, up 28.57% from Rs 28.00 crore in Q1 FY26. These are reported actuals, not estimates.
Sequentially, revenue was down 5.35% over the March 2026 quarter figure of Rs 187.00 crore, and net profit was up 200.00% from Rs 12.00 crore in Q4 FY26. Operating margin stood at 15% in Q1 FY27 against 16% in the September 2025 quarter, which is the comparison the Lincoln Pharmaceuticals Q2 results print will be read against.
Q2 FY26 Base: The Comparison Lincoln Pharmaceuticals Q2 Results FY27 Must Beat
Lincoln Pharmaceuticals Ltd. reported revenue of Rs 163.00 crore and a profit of Rs 20.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Lincoln Pharmaceuticals Q2 results preview.
Net profit in that base quarter was below the Rs 36.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 163.00 crore sits below the Rs 177.00 crore of the June 2026 quarter, which frames how much sequential movement the Lincoln Pharmaceuticals Q2 results print needs to show growth.
Lincoln Pharmaceuticals Quarterly Results Trend Over the Last Four Quarters
| Quarter | Revenue (Rs Cr) | Net Profit (Rs Cr) |
|---|---|---|
| Q2 FY26 (Sep 2025) | 163.00 | 20.00 |
| Q3 FY26 (Dec 2025) | 166.00 | 29.00 |
| Q4 FY26 (Mar 2026) | 187.00 | 12.00 |
| Q1 FY27 (Jun 2026) | 177.00 | 36.00 |
Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company’s exchange filings, and they are the only basis this Lincoln Pharmaceuticals Q2 results preview uses.
Revenue across those four quarters ranged from Rs 163.00 crore to Rs 187.00 crore, and net profit from Rs 12.00 crore to Rs 36.00 crore. That spread is the honest context for the Lincoln Pharmaceuticals Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.
Key Factors That Could Shape Lincoln Pharmaceuticals Q2 Results FY27
The Lincoln Pharmaceuticals Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Lincoln Pharmaceuticals has already reported.
Export Registrations Set the Market
Selling formulations into Africa, Latin America and Southeast Asia requires country-by-country product registrations, so the addressable market grows with approvals rather than with demand. Tender-based institutional supply in those markets makes shipment timing lumpy.
The March Quarter Has a Pattern
Other income was negative Rs 4 crore in March 2026 and negative Rs 7 crore in March 2025, the only two negative readings in the displayed history. A recurring March-quarter adjustment on the investment book is the most likely reading.
The Balance Sheet Is Effectively Debt Free
Borrowings of Rs 4 crore sit against reserves of Rs 738 crore, and interest rounds to zero in every quarter. The effective tax rate ranged from 18% to 31%, and the stock trades at a price to earnings ratio of 13.02 with return on equity of 12.3%.
Lincoln Pharmaceuticals Q2 Results FY27: Share Price and Valuation Going Into the Print
Lincoln Pharmaceuticals share price today is Rs 626.05 on the NSE, down Rs 6.45 or 1.02% from the previous close of Rs 632.50 on 11 September 2026, ahead of the Lincoln Pharmaceuticals Q2 results announcement.
| Metric | Value (11 September 2026) |
|---|---|
| NSE Symbol | LINCOLN |
| Current Market Price | Rs 626.05 |
| 52-Week High | Rs 790.00 |
| 52-Week Low | Rs 450.10 |
| Market Capitalisation | Rs 1,254 crore |
| PE Ratio | 13.02 |
| PB Ratio | 1.66 |
| EPS (TTM) | Rs 48.08 |
| Book Value per Share | Rs 378.00 |
| Debt to Equity | 0.01 |
| Return on Equity | 12.3% |
| 50-Day Moving Average | Rs 606.62 |
| 200-Day Moving Average | Rs 581.68 |
| RSI (14) | 59.08 |
The stock trades above both its 50-day average of Rs 606.62 and its 200-day average of Rs 581.68, with a 14-day RSI of 59.08. None of this is a view on where the shares go once the Lincoln Pharmaceuticals Q2 results are announced, and no price target is offered here.
Download the Univest iOS App or Univest Android App to track Lincoln Pharmaceuticals Ltd. live price and quarterly earnings updates.
What Investors Should Watch When Lincoln Pharmaceuticals Q2 Results Are Announced
Four lines carry most of the information in a company of this size, and reading them in order keeps the Lincoln Pharmaceuticals Q2 results print in proportion.
- Revenue against the Rs 163.00 crore reported in the September 2025 base quarter
- Net profit against a profit of Rs 20.00 crore in that same quarter
- Operating margin against 15% in Q1 FY27
- Any exceptional item, provision or one-off gain disclosed alongside the numbers
A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Lincoln Pharmaceuticals Q2 results announcement should be read together with the notes to the results rather than the headline alone.
Conclusion on Lincoln Pharmaceuticals Q2 Results FY27
The Lincoln Pharmaceuticals Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Lincoln Pharmaceuticals Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.
On that basis the Lincoln Pharmaceuticals Q2 results FY27 print faces a base of Rs 163.00 crore in revenue and a profit of Rs 20.00 crore, with the most recent quarter having delivered Rs 177.00 crore and a profit of Rs 36.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Lincoln Pharmaceuticals, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Lincoln Pharmaceuticals Q2 Results FY27
What is the Lincoln Pharmaceuticals Q2 results date for FY27?
Ans. The Lincoln Pharmaceuticals Q2 results date for FY27 is not confirmed. Lincoln Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 11 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.
What quarter do the Lincoln Pharmaceuticals Q2 results 2026 cover?
Ans. The Lincoln Pharmaceuticals Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Lincoln Pharmaceuticals Ltd. reports revenue, operating profit and net profit for that period, and the Lincoln Pharmaceuticals Q2 results filing also carries the notes to the accounts.
What were the Lincoln Pharmaceuticals Q1 FY27 results?
Ans. Lincoln Pharmaceuticals Ltd. reported revenue of Rs 177.00 crore in Q1 FY27 and a profit of Rs 36.00 crore at the net level. Revenue was up 14.94% versus Q1 FY26 and net profit was up 28.57% from Rs 28.00 crore in Q1 FY26.
What were Lincoln Pharmaceuticals Q2 FY26 results in the September 2025 quarter?
Ans. Lincoln Pharmaceuticals Ltd. reported revenue of Rs 163.00 crore and a profit of Rs 20.00 crore in Q2 FY26. Operating margin was 16%. Those figures form the base for the Lincoln Pharmaceuticals Q2 results FY27 comparison.
What are the main Lincoln Pharmaceuticals Q2 results expectations this quarter?
Ans. No verified analyst estimate is publicly available. The Lincoln Pharmaceuticals Q2 results expectations centre on revenue against the Rs 163.00 crore base, net profit against a profit of Rs 20.00 crore, operating margin against 15% in Q1 FY27, and any exceptional item disclosed with the numbers.
What is Lincoln Pharmaceuticals share price today ahead of the Q2 earnings?
Ans. Lincoln Pharmaceuticals share price is Rs 626.05 on the NSE as of 11 September 2026, down 1.02% from Rs 632.50. The stock is about 20.8% below its 52-week high of Rs 790.00 and 39.1% above its 52-week low of Rs 450.10, at a market capitalisation of Rs 1,254 crore.
Is Lincoln Pharmaceuticals a good stock to buy before the Q2 results?
Ans. This article does not offer a buy, sell or hold recommendation on Lincoln Pharmaceuticals Ltd. The stock trades at a price-to-book ratio of 1.66 with a return on equity of 12.3%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.
